SCP GPW sWIG80 Periodic report · PAP Biznes
Scope Fluidics SA (SCP) · Q1 2026 results
Share price: 142.40 zł · 2026-11-10
Results Q1 2026 vs Q1 2025 · year over year · published 15 May 2026 and 21 May 2025
Net loss widened year on year. The report's language is unchanged.
Only a basic analysis is available for this company at the moment.
1 · Numbers
Loss widened
Net income vs Q1 2025
Net income -13.5M vs -11.0M
Revenue −27.0%
2 · How the report reads
Unchanged
Language tone vs last period
Report language: very upbeat for a company report — about as upbeat as in Q1 2025.
Weak signal: formal report language, not a call.
3 · What stood out
Key theme
The company is building value for the BACTEROMIC project to meet requirements for the Management Board to conduct a Strategic Transaction.
Valuation
Reverse DCF. Free cash flow from the last full fiscal year, grown for 10 years, discounted back, plus a terminal value. “Implied growth” is the rate the current price assumes.
Valuation unavailable: free cash flow and profit were negative in the last full year and on average over the last three, so there is nothing to discount.
Current price
142.40 zł
close of 2026-11-10
Revenue growth, 3 years
−37.2% a year
compound annual rate (CAGR)
Read between the lines
No major shifts flagged this period.
Tone
How upbeat the language was, compared with other companiesiTone counts positive minus negative finance words, adjusted for length. Executives mostly speak positively, so the labels compare each call with every company's latest call: “typical” is the middle third, “very upbeat” the top tenth, “cautious” the bottom tenth.. Dot: Q1 2026. Ring: Q1 2025.
Very upbeat for a company report — about as upbeat as in Q1 2025. Periodic reports carry legally required risk wording, so their tone moves little and is a weak signal.
Sentences that drove the tone
“Based on the experience gained in the process of developing and selling the PCR|ONE technology, the Company expects that in the future, thanks to the unification and optimization of processes, numerous business relationships, as well as the created resources, the development time...”
“In the Board's assessment, the parallel development of two methods will provide the team with greater flexibility in project development and allow for better risk mitigation.”
“Due to the high dynamics of preferences in the M&A market, at the current stage of the Project's development, it is too early to forecast whether and at what stage of development the New”
Full figures
PLN · PAP Biznes report (2026-05-15)
| Metric | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | 27.0K | 37.0K | −27.0% |
| Operating income | -14.5M | -10.4M | Loss widened |
| Net income | -13.5M | -11.0M | Loss widened |
| EPS | -4.25 | -4.03 | Loss widened |
| P/E | 12-mo loss | 7.0 | — |
Topics
Topics are drawn from the full report text, not management commentary.
Most discussed now
- At the current stage of the Group's activities, no decision has been made to carve out additional operating segments due to the early…
- The significant increase compared to the previous year is primarily due to the advance payment related to work associated with the…
- The impact of the political and economic situation in Ukraine on the Group's activities, or on its financial results in the perspective of…
- In the Board's assessment, the adoption of the Extended Model will contribute to creating conditions for parallel and repeatable…
Faded since Q1 2025
- Fading Information obtained during the EAP program will also be used to modify the system and improve the user experience.
- Fading Total tax losses to be settled in subsequent periods
- Fading It aims to obtain FDA opinion regarding the proposed regulatory strategy, the scope of required clinical trials, and the completeness of…
- Fading During the reporting period, no unusual events occurred that would impact assets, liabilities, or equity.
Latest announcements
Official filings, newest first.
- Half-year report · ESPI periodic
- Podpisanie umowy z PARP na dofinansowanie w ramach projektu HYBOLIC · ESPI 29/2026
- Aktualizacja informacji nt. certyfikacji FDA dla rozszerzonej wersji panelu UNI FAST · ESPI 28/2026
- Aktualizacja terminu realizacji pierwszego celu w projekcie HYBOLIC · ESPI 27/2026
- Przyznanie patentu spółce Bacteromic przez Urząd Patentów i Znaków Towarowych Stanów Zjednoczonych · ESPI 26/2026
- SCOPE FLUIDICS S.A. (25/2026) Warunkowe przyznanie dofinansowania dla Edocera · ESPI 25/2026
- Zawarcie przez Bacteromic umowy z dystrybutorem · ESPI 24/2026
- Podpisanie umowy na przeprowadzenie badań klinicznych Panelu PBC systemu BACTEROMIC · ESPI 23/2026